WHAT'S KNOWN ON THIS SUBJECT: Stimulants are widely used as a therapeutic option in the United States and increasingly in Europe. The effect of stimulant drug treatment on academic performance among children with attention-deficit/hyperactivity disorder is unclear. Long-term follow-up studies on the topic are scarce.
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting 5% to 10% of schoolaged children in the United States and Europe. 1, 2 Drug treatment of ADHD with stimulants (and atomoxetine) is now widely used as a therapeutic option in the United States and increasingly in Europe. 1, [3] [4] [5] [6] [7] [8] [9] [10] Nevertheless, the increasing use of ADHD drugs is debated, chiefly because of concerns of overuse, addiction, and uncertainty about the long-term outcomes of treatment.
Stimulant treatment consistently has been shown to be effective in improving inattention, hyperactivity, and impulsivity, the core symptoms of ADHD among school-aged children, 11, 12 but evidence supporting gains in academic performance is equivocal. [13] [14] [15] Controlled trials have reported acutely improved cognitive performance after short durations of treatment, [16] [17] [18] [19] [20] but studies on longerterm academic effects in naturalistic settings are scarce. Existing studies, with follow-up periods from 6 to 13 years, have revealed improved performance in mathematics 21, 22 but inconsistent results for reading improvement. 21, 23 Genderspecific effects have not been reported; several methodologic limitations, including reliance on self-reports of medication use, have hindered interpretation.
In Iceland, the use of methylphenidate stimulants to treat children with ADHD is more common than in most European countries, ∼5 times the use in the neighboring Nordic countries, and reportedly similar to use in the United States. 1, 24 With ∼100% complete national registration of prescription drug utilization and mandatory standardized scholastic tests for all children at age 9 and 12, Iceland offers a unique setting to study academic performance among children who are treated with medication for ADHD.
In this study, we are interested in the effects of stimulant treatment of ADHD on academic progress. Comparing all medicated children with nonmedicated children would be subject to substantial bias from confounding by treatment indication. To limit such bias, we restricted the study to comparisons among children who were treated but whose treatment started at different times. We focused on children starting treatment within the age range of 9 to 12 years and examined the effect of later versus early treatment on academic progress within this group. This restriction leaves a smaller but more homogenous study population, reducing the bias from confounding by indication. Among children treated either early or later within the age range of 9 to 12, we evaluated the hypothesis that a later start of drug treatment for ADHD would adversely affect academic progress in mathematics and language arts.
METHODS

Study Setting and Population
Our source population was all 13 617 children born in 1994, 1995, and 1996 and registered in the Icelandic school system. We obtained data from January 1, 2003 through December 31, 2008 on psychotropic drug prescription fills and standardized test results in mathematics and language arts for this national cohort. By using the personal identification number unique to every citizen, we linked records from the National Population Registry to the Icelandic Medicines Registry and the Database of National Scholastic Examinations. The final study population comprised all children who took a standardized test in both fourth grade (age 9) and seventh grade (age 12) (n = 11 872). Of these children, 11 619 took both mathematics examinations, and 11 542 took both examinations in language arts.
ADHD Drug Exposure
The Icelandic Medicines Registry contains information for each person dispensed prescription drugs as an outpatient since January 1, 2003. Completeness ranges from 93.7% to 99.9% of all dispensedoutpatient prescriptions for the years [2003] [2004] [2005] [2006] [2007] [2008] . For each dispensed prescription in the study, we received information on drug name, number of defined daily doses (DDDs), Anatomic Therapeutic Chemical (ATC) code, date, and pharmacy of the filled prescription.
ADHD drugs were defined according to the World Health Organization ATC classification as drugs within the "nervous system" (N) category, pertaining to the category of "centrally acting sympathomimetics" (N06BA). 25 Chemical substances included were amphetamine (N06BA01), methylphenidate (N06BA04), and atomoxetine (N06BA09). Other chem ical substances within the ATC category N06BA were not available in Iceland or not prescribed to children at the time during the study period. All drugs included had ADHD as their main indication, according to clinical guidelines and drug package inserts. 26, 27 The Icelandic Medicines Registry does not hold information on the indication for drug treatment. In Iceland, however, an ADHD diagnosis must be verified by a pediatric, psychiatric, or neurologic specialist for reimbursement, so it is reasonable to assume that essentially all medicated children fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria 28 for ADHD before treatment.
We defined the start of therapy to be the first prescription after a period of at least 11 months during which no prescriptions for an ADHD drug were filled. After this period, we considered the start date of treatment for each child to be the date of the first dispensing of a prescription for an ADHD drug (stimulant or atomoxetine We assumed that children were being treated concurrently with other psychotropic drugs if a prescription was filled for another psychotropic drug within the 90-day period after the dispensing of an ADHD drug. Other psychotropic drugs were defined as all drugs, other than ADHD drugs, pertaining to ATC drug category N, including antidepressants (N06A), antipsychotics (N05A), anxiolytics, hypnotics and sedatives (N05B, N05C), and other psychotropic drugs (N01, N02, N03, N04, N06C, N06D, N07).
Academic Outcomes
The standardized tests in mathematics and language arts are nationally coordinated assessments within the Icelandic school system, mandatory for all children in fourth grade (9-year-olds) and seventh grade (12-year-olds Tests are scored on a scale of 0.0 to 10.0. We converted the scores to percentiles. We measured change in performance by subtracting the fourth-grade percentile rank from the seventh-grade rank. We defined an academic decline to be a drop of $5.0 percentile points.
Data Analysis
We described medicated and nonmedicated populationsby demographic characteristics and by ADHD drug treatment (ie, type of drugs used, early discontinuation, concurrent psychotropic drug treatment, and treatment on test day) according to time of treatment start. We estimated risks, as well as risk ratios(RRs)anddifferences,fora dropin performance in the mathematics and language arts test. First we estimated crude measures, and then we controlled for performance level on the fourthgrade test (categorized into terciles), gender, birth month (categorized as January-May, June-August, SeptemberDecember), birth place (urban, rural, outside Iceland), school region (urban, rural), change of schools, concurrent psychotropic drug treatment, treatment on test day, and early discontinuation of ADHD drug treatment (,90 DDDs). For stratified analyses, we standardized results to the distribution of the total medicated test-participating population [2003] [2004] [2005] [2006] [2007] [2008] . 29 In these analyses, we excluded children who scored in the lowest fifth percentile on the fourth-grade test, because they were unable to decline in rank by at least 5.0 percentile points. We also conducted a modified Poisson regression analysis to adjust for all confounders simultaneously. 30 Finally, we ran a sensitivity analysis to assess the influence of selection bias that would result if untested children had a different association between later treatment start and academic decline than the children tested. 31 We assumed a range of reference risks and RRs in the group of children not taking either or both examinations. For those who received early treatment, we assumed values of 25%, 33%, 50%, and 75% for the risk of academic decline. To each of these assumed values, we then applied a range of 0% to 100% risk of decline for children who received later treatment, because they could have had either a greater or lesser academic decline than test-participating children. These assumptions produced a range of RRs from 0.0 to 4.0 among non-test participants with later treatment, which we then took into account to get an overall estimate that included projected results from these missing children.
We used PASW Statistics (version 18; SPSS Inc, Chicago, IL) and Excel spreadsheets (Microsoft, Redmond, WA) to run analyses. This study was approved by the National Bioethics Committee (VSNb2008040016/03-7) and the Data Protection Authority (2008040343) in Iceland.
RESULTS
Of the 13 617 children registered in the Icelandic school system, 1029 children (8%) were treated with ADHD drugs at any time during the study period. Test participation, that is, children taking tests in both fourth and seventh grade in either mathematics or language arts, was lower for the total medicated population (72%) than the nonmedicated general population (88%) (Fig 1) . Of 317 children who began treatment between the fourth-and seventh-grade tests, 236 took both tests, resulting in 65%, 85%, and 75% participation for children starting medication at #12 months, 13 to 24 months, and 25 to 36 months, respectively, after the date of fourth-grade ARTICLE tests. Demographic and baseline characteristics among test participants varied only slightly by timing of treatment start (Table 1) . Overall, boys were more likely to be medicated than girls, as were children born in the last third of the calendar year compared with those born earlier. Medicated children scored considerably lower on their fourth-grade tests (taken before their start of treatment) than the nonmedicated population.
Nearly all medicated test-participating children were treated with methylphenidate (96%); 9% were treated simultaneously with the nonstimulant atomoxetine, and 34% were treated concurrently with another psychotropic drug (Table 2) . Methylphenidate was used mainly in extended-release formulations. Of the medicated population, 14% discontinued treatment within 3 months of initiation; that is, they filled ,90 DDDs of an ADHD drug. Children who started treatment within 12 months after fourth-grade tests received, on average, more than double the supply (filled DDDs) of ADHD drugs before tests in seventh grade, compared with those who started later (Table 2) .
Change in Academic Performance
Among children in the nonmedicated general population, performance on average did not change much between tests in fourth and seventh grade; the crude mean percentile score change was a rise of 0.4 (95% confidence interval [CI]: 0.0-0.8) in mathematics and 0.0 (95% CI: 20.3 to 0.4) in language arts. In contrast, mean performance level among medicated children declined. The decline was concentrated among those with later treatment initiation and was much more striking for mathematics than for language arts, with a mean decline of 9.4 percentile points in mathematics for those with delayed treatment initiation (Table 3) . In mathematics, the risk of a decline of $5.0 percentile points was high among all medicated students, but especially high (crude RR: 1.8; 95% CI: 1.3-2.5) for children who started treatment 25 to 36 months after their fourth-grade test. The absolute increase in risk of a decline in mathematics for the later starters on medication was 32%
FIGURE 1
Origin of study population.
a Prevalent users are children already being treated before the fourth-grade tests.
b Incidence users are children who began treatment after the fourth-grade tests. (95% CI: 14%-48%). For language arts, in contrast, the crude RR of academic decline with later treatment was 1.1 (95% CI: 0.7-1.7), and the absolute increase in risk for academic decline among later starters was only 4% (95% CI: 214% to 22%). Table 5 shows the association between later start of ADHD drug treatment and decline in language arts performance stratified by children' s performance on their fourth-grade test, gender, and concurrent psychotropic drug treatment. The adjusted effect estimates did not differ much from the crude estimates and indicated weak associations. The estimated effect of later treatment on decline in language arts was elevated slightly for boys (RR: 1.5), but showed an inverse association for girls (RR: 0.6). There was an effect among those still being treated on test day in seventh grade (RR: 1.6), but not among those no longer being treated (RR: 0.8).
The adjusted estimates of the effect of later drug treatment on academic performance remained the same or changed only minimally when we Any psychotropic drug, n (%) 33 (39) 22 (24) 25 (41) Antidepressants, n (%)
25 (29) 20 (22) 17 (28) Amitryptiline, n (%)
12 (14) 8 (9) 5 (8) Antipsychotic, n (%)
12 (14) 7 (8) 12 ( Figure 2 displays the estimated RR from the main analysis adjusted for hypothetical selection bias (y axis) given the assumed RRs among nontest participants (x axis). The depicted lines, 1 for each assumed reference risk, represent adjusted RRs for a range of associations between later treatment and academic decline among non-test participant children. These adjusted RRs varied from 1.0 to 2.2 in mathematics and from 0.6 to 1.7 in language arts. The sensitivity analysis indicates that the basic findings would look roughly the same over a broad range of assumptions about the risks and associations among children who did not take both tests.
Sensitivity Analysis
DISCUSSION
The results of this population-based, nationwide study indicate that earlier treatment with ADHD drugs between the ages of 9 and 12 years is associated with a lower risk of a decline in academic performance, particularly in mathematics. Our data reveal that the apparent advantage of earlier treatment differs for boys and girls. Girls show a definite benefit only in mathematics, whereas boys show marginal benefits in both mathematics and language arts.
The study has several important limitations. First, we have no information about the underlying ADHD diagnosis, subtype, severity of the condition, or potential comorbid learning or psychiatric disorders. In Iceland, the studied The gender difference in our data could reflect random variability from small numbers, but it also might be consequent torealdifferencesintheacademic benefit of stimulant treatment. Girls diagnosed with ADHD present predominantly with symptoms of inattention and have lower levels of hyperactivity than boys with ADHD, 37, 38 which may play a role in how early the disorder is detected and when treatment starts. Previous studies, however, have found neither gender nor ADHD subtype as modifiers of stimulant treatment outcomes. 20, 39, 40 The results of this nationwide follow-up study indicate that early, rather than later, initiation of drug treatment is associated with a reduced risk of declining academic performance among boys and girls with ADHD, especially in mathematics. 
